<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21493" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Extrapyramidal Symptoms</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>D'Souza</surname>
            <given-names>Ryan S.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hooten</surname>
            <given-names>W M.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan D'Souza declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>W Hooten declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21493.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Extrapyramidal side effects (EPS), commonly referred to as drug-induced movement disorders are among the most common adverse drug effects patients experience from dopamine-receptor blocking agents. A variety of movement phenotypes has since been described along the EPS spectrum, including dystonia, akathisia, and parkinsonism, which occur more acutely, as well as more chronic manifestations of tardive akathisia and tardive dyskinesia. This activity reviews the cause, pathophysiology, and presentation of EPS and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the types of drugs known to cause EPS.</p></list-item><list-item><p>Differentiate the types of EPS symptoms.</p></list-item><list-item><p>Summarize the treatment of EPS.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by EPS.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21493&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21493">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21493.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Extrapyramidal side effects (EPS), commonly referred to as drug-induced movement disorders are among the most common adverse drug effects patients experience from dopamine-receptor blocking agents. It was first described in 1952 after chlorpromazine-induced symptoms resembling Parkinson disease.<xref ref-type="bibr" rid="article-21493.r1">[1]</xref>&#x000a0;A variety of movement phenotypes&#x000a0;has&#x000a0;since been described along the EPS spectrum, including dystonia, akathisia, and parkinsonism, which occur more acutely, as well as more chronic manifestations of tardive akathisia and tardive dyskinesia. The symptoms of EPS are debilitating, interfering with social functioning and communication, motor tasks, and activities of daily living. This is often associated with poor quality of life and abandonment of therapy, which may result in disease relapse and re-hospitalization, particularly in schizophrenic patients stopping pharmacologic therapy.<xref ref-type="bibr" rid="article-21493.r2">[2]</xref></p>
      </sec>
      <sec id="article-21493.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Centrally-acting,&#x000a0;dopamine-receptor blocking agents, namely the first-generation antipsychotics haloperidol and phenothiazine neuroleptics, are the most common medications associated with EPS. While EPS occurs less frequently with atypical antipsychotics, the risk of EPS increases with dose escalation.<xref ref-type="bibr" rid="article-21493.r3">[3]</xref> Other agents that block central dopaminergic receptors have also been identified as causative of EPS, including antiemetics (metoclopramide, droperidol, and prochlorperazine),<xref ref-type="bibr" rid="article-21493.r4">[4]</xref><xref ref-type="bibr" rid="article-21493.r5">[5]</xref> lithium,<xref ref-type="bibr" rid="article-21493.r6">[6]</xref> serotonin reuptake inhibitors (SSRIs),<xref ref-type="bibr" rid="article-21493.r7">[7]</xref> stimulants,<xref ref-type="bibr" rid="article-21493.r8">[8]</xref> and tricyclic antidepressants (TCAs).<xref ref-type="bibr" rid="article-21493.r7">[7]</xref> In rare situations, antivirals, antiarrhythmics, and valproic acid have also been implicated.<xref ref-type="bibr" rid="article-21493.r9">[9]</xref></p>
      </sec>
      <sec id="article-21493.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Rates of EPS are dependent on the class of medication administered. First-generation neuroleptics were associated with EPS in 61.6% of patients in a study of institutionalized patients with schizophrenia.<xref ref-type="bibr" rid="article-21493.r10">[10]</xref> Rates of EPS have declined with atypical antipsychotics with clozapine having the lowest risk and risperidone the highest.<xref ref-type="bibr" rid="article-21493.r11">[11]</xref> In terms of antiemetics with a dopamine D2 receptor antagonist effect, EPS incidence is cited to be between 4% to 25% with metoclopramide<xref ref-type="bibr" rid="article-21493.r12">[12]</xref><xref ref-type="bibr" rid="article-21493.r13">[13]</xref><xref ref-type="bibr" rid="article-21493.r14">[14]</xref>&#x000a0;and between 25% to 67% with prochlorperazine.<xref ref-type="bibr" rid="article-21493.r15">[15]</xref><xref ref-type="bibr" rid="article-21493.r16">[16]</xref></p>
        <p>Risks factors include a history of prior EPS and high medication dose.<xref ref-type="bibr" rid="article-21493.r17">[17]</xref>&#x000a0;Elderly females are more susceptible to drug-induced parkinsonism and tardive dyskinesia,<xref ref-type="bibr" rid="article-21493.r18">[18]</xref><xref ref-type="bibr" rid="article-21493.r19">[19]</xref>&#x000a0;while young males manifest with more dystonic reactions.<xref ref-type="bibr" rid="article-21493.r20">[20]</xref></p>
      </sec>
      <sec id="article-21493.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The mechanism of EPS is thought to be due to the antagonistic binding of dopaminergic D2 receptors within the mesolimbic and mesocortical pathways of the brain. However, the antidopaminergic action in the caudate nucleus and other basal ganglia may also contribute significantly to the occurrence of EPS.<xref ref-type="bibr" rid="article-21493.r21">[21]</xref></p>
      </sec>
      <sec id="article-21493.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Researchers previously hypothesized that the faster dissociation of atypical antipsychotics from the dopamine receptor, compared to typical antipsychotics, explained the reduced incidence of EPS. However, a recent study by Sykes utilized a novel time-resolved fluorescence energy transfer assay to demonstrate that binding kinetics and association rates, not dissociation, correlate more with EPS.<xref ref-type="bibr" rid="article-21493.r22">[22]</xref></p>
      </sec>
      <sec id="article-21493.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>There is a wide spectrum of EPS presentations. Dystonia most often occurs within 48 hours of drug exposure in 50% of cases, and within five days in 90% of cases.<xref ref-type="bibr" rid="article-21493.r23">[23]</xref> On physical exam, dystonia manifests with involuntary muscle contractions resulting in abnormal posturing or repetitive movements. It may affect muscles in different body parts, including the back and extremities (opisthotonus), neck (torticollis), jaw (trismus), eyes (oculogyric crisis), abdominal wall, and pelvic muscles (tortipelvic crisis), and facial and tongue muscles (buccolingual crisis).<xref ref-type="bibr" rid="article-21493.r24">[24]</xref> The provider must evaluate these patients for pain and particularly difficulty in breathing, swallowing, and speech.</p>
        <p>Akathisia is characterized by a subjective feeling of internal restlessness and a compelling urge to move, leading to the objective observation of repetitive movements comprising leg crossing, swinging, or shifting from one foot to another.<xref ref-type="bibr" rid="article-21493.r19">[19]</xref> The onset is usually within four weeks of starting or increasing the dosage of the offending medication. Due to its often vague and non-specific presentation of nervousness and discomfort, akathisia is often misdiagnosed as anxiety, restless leg syndrome, or agitation. In an attempt to treat these incorrect diagnoses, the provider may subsequently increase anti-psychotic or SSRI medications, further exacerbating akathisia.<xref ref-type="bibr" rid="article-21493.r19">[19]</xref><xref ref-type="bibr" rid="article-21493.r25">[25]</xref>&#x000a0;This failure to correctly diagnose can be detrimental as the severity of akathisia is linked to suicidal ideation, aggression, and violence.<xref ref-type="bibr" rid="article-21493.r26">[26]</xref> The provider must also note that withdrawal akathisia may occur with discontinuation or dose reduction of antipsychotic medication, and is typically self-limited lasting within six weeks.<xref ref-type="bibr" rid="article-21493.r19">[19]</xref></p>
        <p>Drug-induced parkinsonism presents as tremor, rigidity, and slowing of motor function in the truncal region and extremities. The classic appearance is an individual with masked facies, stooped posture, and a slow shuffling gait. Gait imbalance and difficulty rising from a seated position are often noted.<xref ref-type="bibr" rid="article-21493.r9">[9]</xref><xref ref-type="bibr" rid="article-21493.r27">[27]</xref></p>
        <p>Finally, tardive dyskinesia manifests as involuntary choreoathetoid movements affecting orofacial and tongue muscles, and less commonly the truncal region and extremities. While symptoms are typically not painful, they may impede social interaction and cause difficulty in chewing, swallowing, and talking.<xref ref-type="bibr" rid="article-21493.r28">[28]</xref></p>
      </sec>
      <sec id="article-21493.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In most cases, laboratory and imaging tests are not required. The diagnosis is apparent from an accurate history and physical exam, especially noting a history of medication exposure.</p>
      </sec>
      <sec id="article-21493.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>If a patient is experiencing acute onset of EPS, particularly dystonia, the provider must assess if an emergency airway intervention is necessary as laryngeal and pharyngeal dystonic reactions may increase the risk of imminent respiratory arrest. Dystonic reactions are rarely life-threatening, and the provider should discontinue the offending agent and manage pain if present. If the causative medication is a typical first-generation antipsychotic, switching to an atypical antipsychotic may be trialed. Administration of an antimuscarinic agent (benztropine, trihexyphenidyl) or diphenhydramine may relieve dystonia within minutes.<xref ref-type="bibr" rid="article-21493.r21">[21]</xref> In cases of tardive dystonia, additional therapeutic strategies include administration of benzodiazepine,<xref ref-type="bibr" rid="article-21493.r21">[21]</xref> injection of botulinum toxin for facial dystonia,<xref ref-type="bibr" rid="article-21493.r29">[29]</xref><xref ref-type="bibr" rid="article-21493.r30">[30]</xref>&#x000a0;trial of muscle relaxant (e.g., baclofen),<xref ref-type="bibr" rid="article-21493.r30">[30]</xref> trial of dopamine-depleting agents (e.g. tetrabenazine),<xref ref-type="bibr" rid="article-21493.r30">[30]</xref> and consideration of deep-brain stimulation or pallidotomy for refractory cases.<xref ref-type="bibr" rid="article-21493.r30">[30]</xref><xref ref-type="bibr" rid="article-21493.r31">[31]</xref></p>
        <p>For the treatment of akathisia, strategies similar to managing dystonia are employed, including stopping or reducing the dosage of the offending medication, switching to an atypical antipsychotic if a typical first-generation antipsychotic was the offending drug, and administering anti-muscarinic agents. Additional therapeutic strategies more specific to akathisia include administration of a beta-blocker (most commonly propranolol), amantadine, clonidine, benzodiazepines, mirtazapine, mianserin (tetracyclic antidepressant), cyproheptadine, and propoxyphene.<xref ref-type="bibr" rid="article-21493.r32">[32]</xref><xref ref-type="bibr" rid="article-21493.r33">[33]</xref></p>
        <p>Tardive dyskinesia is treated by withdrawal or dose reduction of the causative medication, switching to an atypical antipsychotic, withdrawal of concurrent antimuscarinic medications (although trihexyphenidyl has been reported to be therapeutic<xref ref-type="bibr" rid="article-21493.r34">[34]</xref>), injection of botulinum toxin for facial dyskinesia,<xref ref-type="bibr" rid="article-21493.r35">[35]</xref> benzodiazepines,<xref ref-type="bibr" rid="article-21493.r36">[36]</xref> amantadine,<xref ref-type="bibr" rid="article-21493.r36">[36]</xref> and trial of dopamine-depleting medications (e.g. tetrabenazine<xref ref-type="bibr" rid="article-21493.r37">[37]</xref>). Interestingly, the trial of levetiracetam, zonisamide, pregabalin, vitamin B6, and vitamin E have also been reported as therapeutic.<xref ref-type="bibr" rid="article-21493.r28">[28]</xref><xref ref-type="bibr" rid="article-21493.r38">[38]</xref></p>
        <p>Drug-induced parkinsonism is treated with discontinuation or dose reduction of the causative medication, switching to an atypical antipsychotic, and administration of medications used for Parkinson disease, including amantadine, antimuscarinic agents, dopamine agonists, and levodopa.<xref ref-type="bibr" rid="article-21493.r27">[27]</xref></p>
      </sec>
      <sec id="article-21493.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>EPS may be challenging to distinguish from other idiopathic movement disorders. Muscle rigidity and tension are nonspecific symptoms that may be observed in neuroleptic malignant syndrome, serotonin syndrome, and other movement disorders. Chorea and athetosis are also present in Huntington disease (distinguished based on family history and genetic testing), Sydenham chorea (identified with a history of streptococcal infection), Wilson disease (adolescent-onset with a defect in copper metabolism), and cerebrovascular lesions.<xref ref-type="bibr" rid="article-21493.r39">[39]</xref><xref ref-type="bibr" rid="article-21493.r40">[40]</xref>&#x000a0;The flat facial expression, psychomotor slowing, and low energy level in akathisia may mimic the negative symptoms of schizophrenia. In addition, restlessness in akathisia may also appear similar to anxiety and psychotic agitation.<xref ref-type="bibr" rid="article-21493.r41">[41]</xref>&#x000a0;If dementia accompanies parkinsonian signs and other motor abnormalities, the provider should evaluate the patient for Parkinson disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.<xref ref-type="bibr" rid="article-21493.r40">[40]</xref>&#x000a0;Interestingly, up to a third of new-onset schizophrenic patients who have never been medicated may present with parkinsonian signs.<xref ref-type="bibr" rid="article-21493.r42">[42]</xref></p>
      </sec>
      <sec id="article-21493.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>EPS typically resolve spontaneously or improve with pharmacologic interventions. Acute dystonic reactions are often transient, but late-onset and persistent tardive dystonia have been described in the literature where symptoms persisted for years.<xref ref-type="bibr" rid="article-21493.r43">[43]</xref> A study of 107 cases of tardive dystonia reported that only 14% of patients achieved remission over a mean follow-up period of 8.5 years.<xref ref-type="bibr" rid="article-21493.r44">[44]</xref> Similarly, while acute akathisia may spontaneously resolve or improve with appropriate&#x000a0;medication, studies have reported cases of tardive akathisia persisting over many years.<xref ref-type="bibr" rid="article-21493.r45">[45]</xref> Tardive dyskinesia also persists chronically with a cumulative persistence rate as high as 82% in a study of patients with schizophrenia.<xref ref-type="bibr" rid="article-21493.r46">[46]</xref></p>
      </sec>
      <sec id="article-21493.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Antipsychotic-induced and metoclopramide-induced laryngeal dystonia has been reported predominantly in young males.<xref ref-type="bibr" rid="article-21493.r47">[47]</xref>&#x000a0;Rhabdomyolysis is a rare complication of drug-induced dystonia, especially if prolonged dystonia is present.<xref ref-type="bibr" rid="article-21493.r48">[48]</xref> While dystonic storm typically occurs in patients with primary known dystonia (e.g., Wilson disease, DYT1 dystonia), triggers typically include infection and medication adjustment in a significant number of cases.<xref ref-type="bibr" rid="article-21493.r49">[49]</xref> A dystonic storm is a life-threatening situation that manifests with fever, tachycardia, tachypnea, hypertensive crisis, diaphoresis, dysphagia, and respiratory failure.<xref ref-type="bibr" rid="article-21493.r49">[49]</xref> The manifestation of EPS in schizophrenic patients&#x000a0;is associated with poor compliance with other atypical antipsychotic medications, which may subsequently lead to a relapse of schizophrenia and hospitalization.<xref ref-type="bibr" rid="article-21493.r2">[2]</xref>&#x000a0;Failure&#x000a0;to correctly diagnose&#x000a0;and treat EPS&#x000a0;is linked to suicidal ideation, aggression, and violence.<xref ref-type="bibr" rid="article-21493.r26">[26]</xref></p>
      </sec>
      <sec id="article-21493.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>While some&#x000a0;drug-induced movement disorders may last a few minutes, others may last long-term for weeks to years, and may potentially lead to contractures, bony deformities, or significant motor impairment. Physical medicine and rehabilitation consultation may provide useful treatment modalities that have shown efficacy in alleviating dystonia, including relaxation training, biofeedback, transcutaneous electrical nerve stimulation (TENS), and percutaneous dorsal column stimulation.<xref ref-type="bibr" rid="article-21493.r50">[50]</xref> Physical and occupational therapy is paramount, leading to improvement in gait and mobility. In patients with oromandibular or laryngeal involvement, speech therapy may assist with dysphagia and communication barriers. In presentations of EPS refractory to pharmacologic management, neurosurgical consultation may be beneficial to explore deep brain stimulation, thalamotomy, and pallidotomy.</p>
      </sec>
      <sec id="article-21493.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The spectrum of acute symptoms in EPS is distressing, especially with painful torticollis, oculogyric crisis, and bulbar type of speech. If left untreated, it may cause dehydration, infection, pulmonary embolism, rhabdomyolysis, respiratory stridor, and obstruction.<xref ref-type="bibr" rid="article-21493.r4">[4]</xref><xref ref-type="bibr" rid="article-21493.r24">[24]</xref><xref ref-type="bibr" rid="article-21493.r51">[51]</xref><xref ref-type="bibr" rid="article-21493.r52">[52]</xref>&#x000a0;To this end, studies investigating the administration of prophylactic anticholinergic medications to prevent or reduce EPS have been performed. Authors have cautioned that prophylactic anticholinergic medications have distressing peripheral side-effects, including dry mouth, urinary disturbances, and constipation, as well as undesirable central effects comprising cognitive dysfunction and delirium.<xref ref-type="bibr" rid="article-21493.r53">[53]</xref> This long-term prophylactic administration of anticholinergic medications in schizophrenia patients taking antipsychotics may worsen underlying cognitive impairment and subsequently worsen the quality of life.<xref ref-type="bibr" rid="article-21493.r53">[53]</xref> Thus, while current guidelines generally do not recommend the prophylactic or long-term use of anticholinergics in schizophrenic patients taking antipsychotics, this decision should be made on a case-by-case basis with meticulous risk-benefit analysis. In the emergency medicine realm, a meta-analysis demonstrated that prophylactic diphenhydramine reduces EPS in patients receiving bolus administration of antiemetic (with a dopamine D2 antagonist effect), but not when the antiemetic was given as an infusion; thus, this meta-analysis concluded that the most effective strategy would be to administer the antiemetic as an infusion without anticholinergic prophylaxis.</p>
        <p>While typical, first-generation antipsychotics are used less frequently today, the provider must also be cognizant that even second-generation atypical antipsychotics may lead to EPS, although at a lower incidence. Abouzaid and colleagues recently assessed the economic burden of EPS due to atypical antipsychotics in schizophrenia patients. During a 12-month follow-up period, 12.6% of patients experienced EPS. Compared to those without EPS, patients who did experience EPS had more schizophrenia-related and all-cause hospitalizations, schizophrenia-related emergency room visits, and higher schizophrenia-related and all-cause total healthcare, inpatient, and prescription medication costs.<xref ref-type="bibr" rid="article-21493.r54">[54]</xref></p>
        <p>Psychiatric nurses and pharmacists should educate patients about EPS. Nurses monitor patients and consult with the team if issues persist. Pharmacists review acute and chronic medications for doses and interactions. [Level 5]</p>
      </sec>
      <sec id="article-21493.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21493&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21493">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/extrapyramidal-symptoms/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21493">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21493/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21493">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21493.s16">
        <fig id="article-21493.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Parkinson Gait, Involuntary Movement, Festinant Gait Contributed by RS Kumar, MD&#x000a0;</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Parkinsons__gait.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21493.s17">
        <fig id="article-21493.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Simulation of Cogwheel Rigidity, Parkinson's Disease, Tremor, Stop and Go effect during a range of motion maneuver Contributed by Dr. Raju S. Menon (https://www.youtube.com/watch?v=8xxe2WWWoYI)</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Simulation__of____Cog__wheel__rigidity.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21493.s18">
        <fig id="article-21493.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Shuffling gait in parkinson disease Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="shufflinggait" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21493.s19">
        <title>References</title>
        <ref id="article-21493.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rifkin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal side effects: a historical perspective.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>48 Suppl</volume>
            <fpage>3</fpage>
            <page-range>3-6</page-range>
            <pub-id pub-id-type="pmid">2887555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frances</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiden</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Promoting compliance with outpatient drug treatment.</article-title>
            <source>Hosp Community Psychiatry</source>
            <year>1987</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>1158</fpage>
            <page-range>1158-60</page-range>
            <pub-id pub-id-type="pmid">3666712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farah</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Atypicality of atypical antipsychotics.</article-title>
            <source>Prim Care Companion J Clin Psychiatry</source>
            <year>2005</year>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>268</fpage>
            <page-range>268-74</page-range>
            <pub-id pub-id-type="pmid">16498489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Souza</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Mercogliano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ojukwu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of prophylactic anticholinergic medications to decrease extrapyramidal side effects in patients taking acute antiemetic drugs: a systematic review and meta-analysis.</article-title>
            <source>Emerg Med J</source>
            <year>2018</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>325</fpage>
            <page-range>325-331</page-range>
            <pub-id pub-id-type="pmid">29431143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.</article-title>
            <source>Arch Intern Med</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>149</volume>
            <issue>11</issue>
            <fpage>2486</fpage>
            <page-range>2486-92</page-range>
            <pub-id pub-id-type="pmid">2684075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rifkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quitkin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal side effects with lithium treatment.</article-title>
            <source>Am J Psychiatry</source>
            <year>1978</year>
            <month>Jul</month>
            <volume>135</volume>
            <issue>7</issue>
            <fpage>851</fpage>
            <page-range>851-3</page-range>
            <pub-id pub-id-type="pmid">665801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madhusoodanan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alexeenko</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>148</fpage>
            <page-range>148-56</page-range>
            <pub-id pub-id-type="pmid">20680187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taba</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Psychostimulants and movement disorders.</article-title>
            <source>Front Neurol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>75</fpage>
            <pub-id pub-id-type="pmid">25941511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohlega</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Al-Foghom</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced Parkinson`s disease. A clinical review.</article-title>
            <source>Neurosciences (Riyadh)</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-21</page-range>
            <pub-id pub-id-type="pmid">23887211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tuisku</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wahlbeck</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients.</article-title>
            <source>Am J Psychiatry</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>161</volume>
            <issue>1</issue>
            <fpage>160</fpage>
            <page-range>160-3</page-range>
            <pub-id pub-id-type="pmid">14702266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divac</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Prostran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jakovcevski</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cerovac</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Second-generation antipsychotics and extrapyramidal adverse effects.</article-title>
            <source>Biomed Res Int</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>656370</fpage>
            <pub-id pub-id-type="pmid">24995318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganzini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>McCall</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.</article-title>
            <source>Arch Intern Med</source>
            <year>1993</year>
            <month>Jun</month>
            <day>28</day>
            <volume>153</volume>
            <issue>12</issue>
            <fpage>1469</fpage>
            <page-range>1469-75</page-range>
            <pub-id pub-id-type="pmid">8512437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parlak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Atilla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cicek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parlak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erdur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guryay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karaduman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rate of metoclopramide infusion affects the severity and incidence of akathisia.</article-title>
            <source>Emerg Med J</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>621</fpage>
            <page-range>621-4</page-range>
            <pub-id pub-id-type="pmid">16113179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parlak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Erdur</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Parlak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ergin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turkcuer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tomruk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ayrik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ergin</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Intravenous administration of metoclopramide by 2 min bolus vs 15 min infusion: does it affect the improvement of headache while reducing the side effects?</article-title>
            <source>Postgrad Med J</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>83</volume>
            <issue>984</issue>
            <fpage>664</fpage>
            <page-range>664-8</page-range>
            <pub-id pub-id-type="pmid">17916877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saadah</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine.</article-title>
            <source>Headache</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>143</fpage>
            <page-range>143-6</page-range>
            <pub-id pub-id-type="pmid">1563946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-42</page-range>
            <pub-id pub-id-type="pmid">3828192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedenmalm</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>G&#x000fc;zey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Spigset</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-7</page-range>
            <pub-id pub-id-type="pmid">16633151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeste</surname>
                <given-names>DV</given-names>
              </name>
            </person-group>
            <article-title>Tardive dyskinesia rates with atypical antipsychotics in older adults.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2004</year>
            <volume>65 Suppl 9</volume>
            <fpage>21</fpage>
            <page-range>21-4</page-range>
            <pub-id pub-id-type="pmid">15189108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salem</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagpal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pigott</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2017</year>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>789</fpage>
            <page-range>789-798</page-range>
            <pub-id pub-id-type="pmid">27928948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Otani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tokinaga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasui</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">9934942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manwani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service.</article-title>
            <source>Psychiatr Serv</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>287</fpage>
            <page-range>287-9</page-range>
            <pub-id pub-id-type="pmid">10686232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sykes</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stott</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holliday</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Javitch</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Charlton</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D<sub>2</sub> receptors.</article-title>
            <source>Nat Commun</source>
            <year>2017</year>
            <month>Oct</month>
            <day>02</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>763</fpage>
            <pub-id pub-id-type="pmid">28970469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasricha</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Pehlivanov</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide.</article-title>
            <source>Nat Clin Pract Gastroenterol Hepatol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>138</fpage>
            <page-range>138-48</page-range>
            <pub-id pub-id-type="pmid">16511548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Low</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Goel</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Metoclopramide poisoning in children.</article-title>
            <source>Arch Dis Child</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>310</fpage>
            <page-range>310-2</page-range>
            <pub-id pub-id-type="pmid">7416782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peitl</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Prolo&#x00161;&#x0010d;i&#x00107;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bla&#x0017e;evi&#x00107;-Zeli&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skarpa-Usmiani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peitl</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Symptoms of agitated depression and/or akathisia.</article-title>
            <source>Psychiatr Danub</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-10</page-range>
            <pub-id pub-id-type="pmid">21448111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipinski</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mallya</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Fluoxetine-induced akathisia: clinical and theoretical implications.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>9</issue>
            <fpage>339</fpage>
            <page-range>339-42</page-range>
            <pub-id pub-id-type="pmid">2549018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced parkinsonism.</article-title>
            <source>J Clin Neurol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">22523509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Novitch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Kata</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Medication-Induced Tardive Dyskinesia: A Review and Update.</article-title>
            <source>Ochsner J</source>
            <year>2017</year>
            <season>Summer</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-174</page-range>
            <pub-id pub-id-type="pmid">28638290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vogt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>L&#x000fc;ssi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A].</article-title>
            <source>Nervenarzt</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>79</volume>
            <issue>8</issue>
            <fpage>912</fpage>
            <page-range>912-7</page-range>
            <pub-id pub-id-type="pmid">18551268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cloud</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jinnah</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Treatment strategies for dystonia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-15</page-range>
            <pub-id pub-id-type="pmid">20001425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidailhet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vercueil</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Houeto</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Krystkowiak</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benabid</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cornu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lagrange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000e9;zenas du Montcel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dormont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Blond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Detante</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pillon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ardouin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agid</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dest&#x000e9;e</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pollak</surname>
                <given-names>P</given-names>
              </name>
              <collab>French Stimulation du Pallidum Interne dans la Dystonie (SPIDY) Study Group</collab>
            </person-group>
            <article-title>Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Feb</month>
            <day>03</day>
            <volume>352</volume>
            <issue>5</issue>
            <fpage>459</fpage>
            <page-range>459-67</page-range>
            <pub-id pub-id-type="pmid">15689584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Fleischhacker</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Managing antipsychotic-induced acute and chronic akathisia.</article-title>
            <source>Drug Saf</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-81</page-range>
            <pub-id pub-id-type="pmid">10647977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inada</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Drug-Induced Akathisia].</article-title>
            <source>Brain Nerve</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>1417</fpage>
            <page-range>1417-1424</page-range>
            <pub-id pub-id-type="pmid">29282345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>UJ</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Natural history and treatment of tardive dystonia.</article-title>
            <source>Mov Disord</source>
            <year>1986</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>193</fpage>
            <page-range>193-208</page-range>
            <pub-id pub-id-type="pmid">2904118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alabed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Latifeh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Rifai</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Apr</month>
            <day>13</day>
            <issue>4</issue>
            <fpage>CD000203</fpage>
            <pub-id pub-id-type="pmid">21491376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waln</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An update on tardive dyskinesia: from phenomenology to treatment.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2013</year>
            <volume>3</volume>
            <pub-id pub-id-type="pmid">23858394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tetrabenazine in the treatment of hyperkinetic movement disorders.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-17</page-range>
            <pub-id pub-id-type="pmid">16466307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cloud</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Zutshi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Factor</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Tardive dyskinesia: therapeutic options for an increasingly common disorder.</article-title>
            <source>Neurotherapeutics</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>166</fpage>
            <page-range>166-76</page-range>
            <pub-id pub-id-type="pmid">24310603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Medcalf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hellier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders after stroke.</article-title>
            <source>Age Ageing</source>
            <year>2009</year>
            <month>May</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>260</fpage>
            <page-range>260-6</page-range>
            <pub-id pub-id-type="pmid">19276093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanders</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gillig</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal examinations in psychiatry.</article-title>
            <source>Innov Clin Neurosci</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7-8</issue>
            <fpage>10</fpage>
            <page-range>10-6</page-range>
            <pub-id pub-id-type="pmid">22984647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Extrapyramidal side effects are unacceptable.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>11 Suppl 4</volume>
            <fpage>S397</fpage>
            <page-range>S397-403</page-range>
            <pub-id pub-id-type="pmid">11587887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peralta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Basterra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>de Jal&#x000f3;n</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Moreno-Izco</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cuesta</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders.</article-title>
            <source>Eur Arch Psychiatry Clin Neurosci</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>262</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-8</page-range>
            <pub-id pub-id-type="pmid">21626260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Gollomp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ilson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.</article-title>
            <source>Neurology</source>
            <year>1982</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>1335</fpage>
            <page-range>1335-46</page-range>
            <pub-id pub-id-type="pmid">6128697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiriakakis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Marsden</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>The natural history of tardive dystonia. A long-term follow-up study of 107 cases.</article-title>
            <source>Brain</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>121 ( Pt 11)</volume>
            <fpage>2053</fpage>
            <page-range>2053-66</page-range>
            <pub-id pub-id-type="pmid">9827766</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>UJ</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Fahn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tardive akathisia: an analysis of clinical features and response to open therapeutic trials.</article-title>
            <source>Mov Disord</source>
            <year>1989</year>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-75</page-range>
            <pub-id pub-id-type="pmid">2567492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenback</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>van Harten</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Slooff</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>van Os</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia.</article-title>
            <source>J Psychopharmacol</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>1031</fpage>
            <page-range>1031-5</page-range>
            <pub-id pub-id-type="pmid">19487321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christodoulou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalaitzi</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.</article-title>
            <source>J Psychopharmacol</source>
            <year>2005</year>
            <month>May</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-11</page-range>
            <pub-id pub-id-type="pmid">15888517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavanaugh</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Finlayson</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs.</article-title>
            <source>J Clin Psychiatry</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>8</issue>
            <fpage>356</fpage>
            <page-range>356-7</page-range>
            <pub-id pub-id-type="pmid">6746581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Termsarasab</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frucht</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Dystonic storm: a practical clinical and video review.</article-title>
            <source>J Clin Mov Disord</source>
            <year>2017</year>
            <volume>4</volume>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">28461905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Non-Invasive Brain Stimulation for Treatment of Focal Hand Dystonia: Update and Future Direction.</article-title>
            <source>J Mov Disord</source>
            <year>2016</year>
            <month>May</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-62</page-range>
            <pub-id pub-id-type="pmid">27240806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bertsch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>531</fpage>
            <page-range>531-40</page-range>
            <pub-id pub-id-type="pmid">20814320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levinson</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>1986</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>839</fpage>
            <page-range>839-48</page-range>
            <pub-id pub-id-type="pmid">2875701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyake</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-49</page-range>
            <pub-id pub-id-type="pmid">24102938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21493.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abouzaid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kahler</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Economic burden associated with extrapyramidal symptoms in a medicaid population with schizophrenia.</article-title>
            <source>Community Ment Health J</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-8</page-range>
            <pub-id pub-id-type="pmid">23229052</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
